Compare LSE & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSE | PMVP |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.5M | 71.1M |
| IPO Year | 2023 | 2020 |
| Metric | LSE | PMVP |
|---|---|---|
| Price | $4.25 | $1.44 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.5K | ★ 750.9K |
| Earning Date | 01-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $61.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.20 | $1.02 |
| 52 Week High | $6.98 | $1.88 |
| Indicator | LSE | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 54.96 |
| Support Level | $4.15 | $1.36 |
| Resistance Level | $5.09 | $1.50 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 40.00 | 57.14 |
Leishen Energy Holding Co Ltd is a provider of clean-energy equipment and integrated solutions to the oil and gas industry, with a commitment to providing customers with high-performance, safe, and cost-effective energy solutions. The company's business segments include clean-energy equipment, oil and gas engineering technical services, new energy production and operation, and digitalization and integration equipment. A majority of its revenue is generated from the clean-energy equipment segment, which supplies various equipment, such as reciprocating compressor units, expansion units, wellhead heating systems, wellhead safety control systems, oil-water separation systems, natural gas online sampling systems, oil and gas skid-mounted equipment, and polymer flexible composite pipes.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.